Back Dictionary Export CSV
Filter: Clear
MERGED_REGIMEN_ID MERGED_TUMOUR_ID HEIGHT_AT_START_OF_REGIMEN WEIGHT_AT_START_OF_REGIMEN INTENT_OF_TREATMENT DATE_DECISION_TO_TREAT START_DATE_OF_REGIMEN MAPPED_REGIMEN CLINICAL_TRIAL CHEMO_RADIATION MERGED_PATIENT_ID BENCHMARK_GROUP
220013976 220017959 1.84 85.7 null 2018-05-06 2018-05-06 FLAG N N 220031949 FLAG
220013977 220008422 null 84 Curative (C) 2014-11-19 2014-11-19 Triple / Double Intrathecal Therapy null null 220031952 TRIPLE INTRATHECAL
220013978 220008424 1.95 22.6 Curative (C) 2014-12-02 2014-12-02 Cyclophosphamide+Fludara+TBI Allo N N 220031953 CYCLOPHOSPHAMIDE + FLUDARABINE
220013979 220014564 null null Curative (C) 2013-06-16 2013-08-11 ATG + Busulfan + Fludarabine N N 220031962 ATG + BUSULFAN + FLUDARABINE
220013980 220014564 1.59 60.3 Palliative (P) 2014-10-11 2014-10-11 Triple Intrathecal 02 N 220031962 TRIPLE INTRATHECAL
220013981 220021909 1.85 64 Palliative (P) 2016-02-21 2016-02-22 BOSUTINIB 02 N 220031969 BOSUTINIB
220013982 220022105 1.67 0 Curative (C) 2014-05-03 2014-05-03 ATG + Busulfan + Fludarabine N N 220031971 ATG + BUSULFAN + FLUDARABINE
220013983 220022105 1.57 66 null 2017-06-04 2017-06-14 Methotrexate intrathecal Y null 220031971 METHOTREXATE INTRATHECAL
220013984 220022105 1.52 57.4 Disease modification (D) 2013-05-10 2013-07-06 Methotrexate intrathecal Y N 220031971 METHOTREXATE INTRATHECAL
220013985 220022105 0 55 Disease modification (D) 2018-01-21 2018-01-21 CYCLOPHOSPHAMIDE + FLUDARABINE 01 N 220031971 CYCLOPHOSPHAMIDE + FLUDARABINE
220013986 220008427 1.72 115 Adjuvant (A) 2014-03-29 2014-03-31 AML Int Guide ADE 10+3+5 (1) null null 220031997 ADE
220013987 220008427 0 39.7 Curative (C) 2015-10-11 2015-10-12 RUXOLITINIB N Y 220031997 RUXOLITINIB
220013988 220008429 null 56 null null 2014-02-18 Cyclophosphamide+Fludara+TBI Allo N N 220032001 CYCLOPHOSPHAMIDE + FLUDARABINE
220013989 220008430 null 57 Disease modification (D) 2017-07-10 2017-07-17 AML Int Guide ADE 8+3+5 (2) N N 220032004 ADE
220013990 220017963 1.65 62.3 Curative (C) null 2017-06-17 AML16 DA 3+10 null null 220032005 AML16 TRIAL
220013991 220017963 null 55.8 Disease modification (D) 2018-01-05 2018-01-05 BOSUTINIB N N 220032005 BOSUTINIB
220013993 220008433 1.67 23.6 Curative (C) 2014-07-06 2014-07-08 BOSUTINIB N N 220032022 BOSUTINIB
220013994 220008434 null 114 Curative (C) 2016-05-01 2016-07-02 CYCLOPHOSPHAMIDE + FLUDARABINE N N 220032025 CYCLOPHOSPHAMIDE + FLUDARABINE
220013995 220008438 0 88.5 Palliative (P) 2014-08-08 2014-10-05 CYCLOPHOSPHAMIDE + FLUDARABINE Y N 220032027 CYCLOPHOSPHAMIDE + FLUDARABINE
220013996 220008438 1.9 93 Curative (C) 2015-06-19 2015-06-23 ATG + Busulfan + Fludarabine Y N 220032027 ATG + BUSULFAN + FLUDARABINE
220013997 220008440 1.91 78 Disease modification (D) 2017-04-26 2017-05-02 Triple Intrathecal null N 220032029 TRIPLE INTRATHECAL
220013998 220008440 1.85 96.7 Curative (C) 2016-07-31 2016-08-12 FLAG N N 220032029 FLAG
220013999 220008441 1.66 65.9 Curative (C) 2013-09-11 2013-09-11 BOSUTINIB 02 N 220032036 BOSUTINIB
220014000 220008441 1.75 null Disease modification (D) 2016-11-08 2016-11-20 IDARUBICIN + TRETINOIN N N 220032036 IDARUBICIN + TRETINOIN
220014001 220014576 1.67 68.4 Curative (C) 2017-08-12 2017-08-24 RUXOLITINIB N N 220032041 RUXOLITINIB
220014002 220014576 null null Palliative (P) 2016-01-17 2016-03-28 ATG + Busulfan + Fludarabine 02 N 220032041 ATG + BUSULFAN + FLUDARABINE
220014003 220008445 1.7 0 Curative (C) 2014-11-21 2014-11-21 ATG + Busulfan + Fludarabine N N 220032050 ATG + BUSULFAN + FLUDARABINE
220014004 220008448 1.68 50.6 Curative (C) 2017-06-19 2017-06-26 Cyclophosphamide TBI Allograft 2 N 220032050 CYCLOPHOSPHAMIDE
220014005 220008450 1.59 113.8 Curative (C) 2014-11-10 2014-11-10 RUXOLITINIB N N 220032056 RUXOLITINIB
220014006 220008452 null null Not known (9) 2013-01-13 2013-03-01 RUXOLITINIB 99 N 220032058 RUXOLITINIB
220014007 220008453 null 60.9 Not known (9) 2018-01-15 2018-01-15 ATG + Busulfan + Fludarabine N N 220032061 ATG + BUSULFAN + FLUDARABINE
220014008 220008453 1.87 87.8 Curative (C) 2014-04-30 2014-05-14 BOSUTINIB 02 N 220032061 BOSUTINIB
220014009 220008456 1.74 79.4 Not known (9) null 2017-10-10 FLAG N N 220032064 FLAG
220014010 220008457 1.59 0 Disease modification (D) 2014-10-04 2014-11-01 Triple Intrathecal N N 220032067 TRIPLE INTRATHECAL
220014011 220008458 null 20 Curative (C) 2017-04-03 2017-04-03 RUXOLITINIB 2 N 220032067 RUXOLITINIB
220014012 220014583 1.83 null null 2015-08-09 2015-08-13 IDARUBICIN + TRETINOIN N N 220032072 IDARUBICIN + TRETINOIN
220014013 220008462 1.8 56.2 Curative (C) 2015-12-11 2015-12-11 BOSUTINIB N N 220032087 BOSUTINIB
220014014 220008464 1.96 60 Curative (C) 2016-10-03 2017-02-13 BOSUTINIB N N 220032087 BOSUTINIB
220014015 220008465 null 94 Curative (C) 2016-03-04 2016-03-04 AML16 DA 2+5 02 N 220032105 AML16 TRIAL
220014016 220014588 1.79 null Curative (C) 2013-04-16 2013-04-16 AML16 Low Dose Cytarabine 02 N 220032108 AML16 TRIAL
220014018 220014590 null 66.2 Curative (C) 2014-01-19 2014-01-25 Triple / Double Intrathecal Therapy 02 null 220032113 TRIPLE INTRATHECAL
220014019 220008481 null 74 Curative (C) 2016-03-09 2016-03-21 AML Int Guide ADE 8+3+5 (2) N N 220032113 ADE
220014020 220008481 1.74 71.8 Curative (C) 2017-08-04 2017-08-04 RUXOLITINIB null null 220032113 RUXOLITINIB
220014021 220008482 null 95 Curative (C) 2014-05-29 2014-08-22 Idarubicin+Tretinoin Spanish Crse4 null null 220032121 IDARUBICIN + TRETINOIN
220014022 220019869 0 null Curative (C) 2013-10-18 2013-10-18 FLAG 2 N 220032125 FLAG
220014023 220008484 1.63 77.4 Disease modification (D) 2013-11-15 2013-11-15 CYCLOPHOSPHAMIDE 2 N 220032126 CYCLOPHOSPHAMIDE
220014024 220008486 1.69 10.6 Curative (C) 2015-04-14 2015-04-14 FLAG N N 220032131 FLAG
220014025 220008486 1.7 46.9 Not known (9) 2017-03-03 2017-03-04 CYCLOPHOSPHAMIDE + FLUDARABINE 2 N 220032131 CYCLOPHOSPHAMIDE + FLUDARABINE
220014026 220008487 1.41 null Curative (C) 2017-06-27 2017-08-03 Methotrexate intrathecal null null 220032142 METHOTREXATE INTRATHECAL
220014027 220014595 null 56.7 Curative (C) 2013-12-09 2013-12-09 AML16 DA 3+10 null null 220032142 AML16 TRIAL